Modalis Therapeutics Corporation (TYO:4883)

Market Cap	6.92B
Revenue (ttm)	n/a
Net Income (ttm)	-1.51B
Shares Out	76.93M
EPS (ttm)	-27.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,808,700
Average Volume	4,557,815
Open	87.00
Previous Close	88.00
Day's Range	87.00 - 90.00
52-Week Range	66.00 - 203.00
Beta	0.16
RSI	53.97
Earnings Date	Aug 7, 2025

About Modalis Therapeutics

Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target; an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 14
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4883